Q2 2026: The Quarter That Counted For Psychedelics

LOS ANGELES – Q2 2026 gave the psychedelic medicine sector the quarter that practitioners, investors, and regulators had been building up for years. Clinical programs delivered Phase 3 results, the White House signed an executive order, and the FDA cleared its first ibogaine-derived compound for U.S. study. Together, the three months ending June 30 produced a degree of institutional progress the sector has rarely seen in a single window.

The quarter’s most closely tracked result arrived June 22, when Definium Therapeutics (formerly MindMed) announced positive topline data from the Phase 3 Emerge study of DT120, its proprietary lysergide orally disintegrating tablet, in major depressive disorder. The single-dose trial met its primary endpoint and all key secondary efficacy measures, with MADRS scores improving substantially over placebo at week six. Stifel analysts described the findings as having “exceeded expectations with clear and highly robust efficacy.” Participants cleared the end-of-session checklist in an average of under six hours – faster than many in the field had anticipated for an LSD-derived compound. No new safety signals emerged. Definium subsequently disclosed plans to raise $700 million in fresh capital, and a second late-stage study, Ascend, is expected to begin enrollment in mid-2026 with an added low-dose arm.

The policy development of the quarter was the April 18 executive order signed by President Trump, directing the FDA and DEA to establish access pathways for investigational psychedelics under the Right to Try Act, and committing at least $50 million through ARPA-H to match qualifying state programs. Six days later, the FDA issued Commissioner’s National Priority Vouchers to Usona Institute for psilocybin in major depressive disorder (MDD), and Transcend Therapeutics for methylone in PTSD – vouchers that can compress review timelines from months to weeks.

The ibogaine story carried complications at the state level. Texas announced in late March that it would self-fund its own ibogaine research program through UTHealth Houston and UT Medical Branch at Galveston, after no private companies met the funding and revenue-sharing thresholds required under Senate Bill 2308. Legal analysts noted the state statute may need legislative adjustments before funds can flow – a procedural constraint the executive order’s federal matching provision does not automatically resolve.

Also in Q2, Compass Pathways received an FDA priority voucher for COMP360 in treatment-resistant depression (TRD), following February’s second positive Phase 3 readout from the COMP006 study. The company is targeting an NDA submission in Q4 2026, with 26-week durability data expected in early Q3.

Q2 2026 produced a rare alignment of positive late-stage clinical data and consequential federal policy action, a combination that rarely materializes within a single calendar quarter. Two Phase 3 datasets, three FDA priority vouchers, an executive order, and the first domestic clearance for an ibogaine-derived compound all landed in the same stretch. The volume of NDA-stage activity now heading toward the FDA before year-end will test the agency’s capacity, and the structural gap between political urgency around ibogaine and the compound’s clinical readiness remains the sector’s most unresolved question heading into H2 2026.